Research Analysts Set Expectations for AXSM Q3 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Axsome Therapeutics in a research report issued on Thursday, January 16th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.04 per share for the quarter, down from their prior forecast of $0.11. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($4.61) per share.

Other research analysts have also issued research reports about the company. HC Wainwright reiterated a "buy" rating on shares of Axsome Therapeutics in a research report on Tuesday, December 31st. Robert W. Baird lifted their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Truist Financial increased their target price on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the stock a "buy" rating in a report on Monday, January 13th. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Royal Bank of Canada boosted their price objective on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $130.69.

Axsome Therapeutics Stock Down 1.9 %

NASDAQ:AXSM traded down $1.76 during mid-day trading on Monday, reaching $91.93. The stock had a trading volume of 808,350 shares, compared to its average volume of 724,302. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of -14.08 and a beta of 1.04. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $105.00. The stock's 50 day simple moving average is $92.27 and its two-hundred day simple moving average is $89.53.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period last year, the business earned ($1.32) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AXSM. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after purchasing an additional 318 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Axsome Therapeutics during the 2nd quarter worth about $27,000. WCM Investment Management LLC lifted its stake in shares of Axsome Therapeutics by 0.3% in the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company's stock worth $10,191,000 after acquiring an additional 347 shares during the period. US Bancorp DE boosted its holdings in shares of Axsome Therapeutics by 0.3% in the third quarter. US Bancorp DE now owns 133,126 shares of the company's stock valued at $11,964,000 after acquiring an additional 421 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $47,000. Institutional investors own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.